SCHEMBL6663928

SCHEMBL6663928

CC1(C)CC(=CCCN)CC(C)(C)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3086362 0.98
SCHEMBL6661247 0.82
Hydrochloric Acid SCHEMBL3076288 0.80
SCHEMBL11468635 0.73
SCHEMBL3077930 0.73
SCHEMBL6659494 0.62
SCHEMBL6664205 0.62
SCHEMBL11509025 0.62 DPP7 (0.39)
SCHEMBL29339100 0.61 HRH3 (0.33)
SCHEMBL3080695 0.59 DRD3 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100390131-C Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists MERZ PHARMA GMBH & CO KGAA (DE) 2008-05-28 CN claimed
CN-1602292-A Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists MERZ PHARMA GMBH & CO KGAA (DE) 2005-03-30 CN claimed
EP-1442008-A1 UNSATURATED 1-AMINO-ALKYLCYCLOHEXANE NMDA, 5HT3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2004-08-04 EP claimed
WO-2003040084-A1 UNSATURATED 1-AMINO-ALKYLCYCLOHEXANE NMDA, 5HT3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2003-05-15 WO claimed
US-20160136144-A1 COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS MERZ PHARMA GMBH & CO. KGAA (DE) 2016-05-19 US disclosed
EP-2260839-A2 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors Merz Pharma GmbH & Co. KGaA (DE) 2010-12-15 EP disclosed
US-20100227852-A1 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors MERZ PHARMA GMBH & CO. KGAA (DE) 2010-09-09 US disclosed
US-20090124659-A1 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors MERZ PHARMA GMBH & CO. KGAA (DE) 2009-05-14 US disclosed
CN-100390131-C Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists MERZ PHARMA GMBH & CO KGAA (DE) 2008-05-28 CN disclosed
CN-1602292-A Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists MERZ PHARMA GMBH & CO KGAA (DE) 2005-03-30 CN disclosed
US-6828462-B2 Amines such as 3,3,5,5-Tetramethyl-1-vinylcyclohexanamine hydrochloride, used as N-methyl-D-aspartate (NMDA), serotonin and nicotinic acetylcholine receptor antagonists MERZ PHARMA GMBH & CO. KGAA (DE) 2004-12-07 US disclosed
WO-2004037234-A2 COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS MERZ PHARMA GMBH & CO. KGAA (DE) 2004-05-06 WO disclosed